Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.67 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.67 |
| ▸ | CASR | P41180 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9423408 | 0.86 | CNR2 (0.61) | MTNR1AMTNR1BCASRL3MBTL1TDP1 | |
| SCHEMBL27766744 | 0.85 | MTNR1A (0.52) | MTNR1AMTNR1BCASRL3MBTL1TDP1 | |
| SCHEMBL11436413 | 0.85 | L3MBTL1 (0.62) | MTNR1AMTNR1BCASRL3MBTL1TDP1 | |
| SCHEMBL11436469 | 0.85 | L3MBTL1 (0.62) | MTNR1AMTNR1BCASRL3MBTL1TDP1 | |
| SCHEMBL11436414 | 0.85 | L3MBTL1 (0.62) | MTNR1AMTNR1BCASRL3MBTL1TDP1 | |
| SCHEMBL28269689 | 0.84 | MTNR1A (0.51) | MTNR1AMTNR1BL3MBTL1TDP1LMNA | |
| SCHEMBL28269690 | 0.84 | MTNR1A (0.51) | MTNR1AMTNR1BL3MBTL1TDP1LMNA | |
| SCHEMBL6301269 | 0.83 | MTNR1A (0.63) | MTNR1AMTNR1BCASRL3MBTL1TDP1 | |
| SCHEMBL23216480 | 0.81 | MTNR1A (0.52) | MTNR1AMTNR1BCASRL3MBTL1TDP1 | |
| SCHEMBL29664636 | 0.81 | MTNR1A (0.52) | MTNR1AMTNR1BCASRL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943183-B2 | 5-substituted tetralones as inhibitors of ras farnesyl transferase | PFIZER INC (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | WARNER-LAMBERT COMPANY | 2004-03-04 | — | — | US | disclosed |
| EP-1276725-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001079180-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | PTAR1, FNTA, GGPS1 | MTNR1A 2828/4885MTNR1B 3212/4885CASR 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.